
Bayer’s chief executive to step down in 2016
pharmafile | June 4, 2014 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, Germany, Marijn Dekkers
Marijn Dekkers the chief executive of German pharma firm Bayer has set his departure date to the end of 2016.
Dekkers who has been at the Bayer helm since the beginning of 2010, is said to have cited family reasons as the motivation for departing the company.
Bayer says in a statement: “In line with his own wishes, the contract of Dr Marijn Dekkers will be extended by just two years on expiration of the initial five-year period.”
Werner Wenning, Bayer’s chairman of the supervisory board adds: “We are pleased that Dr Dekkers, under whose leadership Bayer has continued its very positive development, will remain with us for a further two years.”
Bayer now has over two years to decide who will succeed Dekkers, but for the time being the firm has confirmed that Werner Baumann will take on the role of chief strategy and portfolio officer, to “ensure continuity in key aspects of Bayer’s future development.”
Replacing Baumann as chief financial officer will be Johannes Dietsch, who is based in Shanghai and will assume Bayer’s CFO role there in China.
Brett Wells
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …

Bayer and Evotec to collaborate on precision cardiology
Bayer and Evotec have announced that they have updated the focus of their collaboration to …






